Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma

Semin Thorac Cardiovasc Surg. Summer 2019;31(2):301-309. doi: 10.1053/j.semtcvs.2019.01.010. Epub 2019 Jan 10.

Abstract

We compared less invasive surgery with conventional surgery for malignant pleural mesothelioma (MPM). We retrospectively reviewed consecutive patients with MPM who received surgery at Hyogo College of Medicine between July 2004 and April 2016. Patients underwent multimodal treatment comprising chemotherapy (neoadjuvant and/or adjuvant) and surgery with or without 54 Gy hemithoracic radiotherapy. Patients were grouped into 3 groups according to the surgery intended: Conventional extrapleural pneumonectomy was intended in Group 1 (until August 2009); less invasive extrapleural pneumonectomy was intended in Group 2 (after September 2009); pleurectomy/decortication was intended in Group 3 (after September 2012). We included 152 patients (median age 64 [37-71] years; 131 men, 21 women), mostly with epithelioid subtypes (91.4%). Of them, 149 (98.0%) underwent neoadjuvant chemotherapy and 117 (77.0%) underwent surgery (60 had extrapleural pneumonectomy and 57 had pleurectomy/decortication). Macroscopic complete resection was achieved in 94.9% (111/117), and the mortality rates at 30 and 90 days were 1.7% (2/117) and 3.4% (4/117), respectively. The overall median survival time and progression-free survival for all 152 patients were 34.9 and 17.4 months. The overall median survival time for Groups 1, 2, and 3 were 18.5, 41.9, and 43.4 months, respectively. The progression-free survival for Groups 1, 2, and 3 were 12.0, 24.5, and 21.8 months, respectively. Compared with conventional surgical techniques, less invasive surgery for MPM yielded lower surgical risks and comparable or improved survival.

Keywords: Extrapleural pneumonectomy; Malignant pleural mesothelioma; Multimodal treatment; Pleurectomy/decortication; Surgery.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery*
  • Male
  • Mesothelioma / mortality
  • Mesothelioma / pathology
  • Mesothelioma / surgery*
  • Mesothelioma, Malignant
  • Middle Aged
  • Neoadjuvant Therapy
  • Pleural Neoplasms / mortality
  • Pleural Neoplasms / pathology
  • Pleural Neoplasms / surgery*
  • Pneumonectomy / adverse effects*
  • Pneumonectomy / mortality
  • Postoperative Complications / etiology*
  • Postoperative Complications / mortality
  • Progression-Free Survival
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Thoracic Surgery, Video-Assisted / adverse effects*
  • Thoracic Surgery, Video-Assisted / mortality
  • Thoracotomy / adverse effects*
  • Thoracotomy / mortality
  • Time Factors